tipifarnib has been researched along with serine in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (serine) | Trials (serine) | Recent Studies (post-2010) (serine) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 23,914 | 115 | 6,084 |
| Protein | Taxonomy | tipifarnib (IC50) | serine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.015 | |
| Cholinesterase | Equus caballus (horse) | 0.016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choudary, A; Freeman, JW; Venkatasubbarao, K | 1 |
1 other study(ies) available for tipifarnib and serine
| Article | Year |
|---|---|
Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Cell Cycle Proteins; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Interleukin-6; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinolones; Serine; STAT3 Transcription Factor; Trans-Activators; Tyrosine; Up-Regulation | 2005 |